Cost of Cancer: Healthcare Expenditures and Economic Impact
Author:
- 13 December 2018
- book chapter
- Published by Springer Nature
- Vol. 213, 7-23
Abstract
Healthcare expenditures for cancer account for a low share of total healthcare expenditures, compared to the relative burden of the disease. The share has also not changed very much over the last decades. Cost for cancer drugs has increased as a share of total expenditures, but this has been offset by a reduction of inpatient hospital care for cancer. Accounting for the cost of cancer should not be limited to healthcare expenditures. Resources are also used for public and private care of cancer patients outside the healthcare sector, for example for palliative care. Informal care by family and friends is an important complement to professional care, and estimates indicate that this amounts to between half and one-third of the costs of formal care. Indirect costs related to the loss of production for persons with cancer are estimated to be of the same magnitude as the direct healthcare expenditures. Indirect costs related to premature mortality dominate the estimate of indirect costs, but those costs have declined over time, despite increasing incomes, due to the reduction in mortality due to cancer in the economically active age groups. Estimates of indirect costs due to morbidity are uncertain and vary significantly between published studies. A full accounting of the costs of cancer should include an estimate of the health burden of cancer. Loss of quality-adjusted life expectancy (QALY) can be measured and valued based on the willingness to pay for a QALY. Such estimates are possible to derive from decisions about allocating resources for cancer. There are few estimates of these costs, but available studies indicate that the intangible costs of lost QALY are by far the dominating cost of cancer. The value for policy-making of costs of cancer estimates increases when results with consistent methods and data are available that allow comparisons between countries and over time. The evidence about the cost of cancer is still limited, but when current scientific progress produces an increasing number of new options for prevention, diagnosis and treatment, studies of the cost of cancer become increasingly important to inform decisions about resource allocation.Keywords
This publication has 10 references indexed in Scilit:
- New insights into the burden and costs of multiple sclerosis in Europe: Results for SwedenMultiple Sclerosis Journal, 2017
- The cost and burden of cancer in the European Union 1995–2014European Journal of Cancer, 2016
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- The Influence of Cost‐Effectiveness and Other Factors on Nice DecisionsHealth Economics, 2014
- Economic burden of cancer across the European Union: a population-based cost analysisThe Lancet Oncology, 2013
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer DiagnosisHealth Affairs, 2013
- How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer TherapiesHealth Affairs, 2012
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in OncologyJNCI: Journal of the National Cancer Institute, 2010
- Cost of breast cancer in Sweden in 2002The European Journal of Health Economics, 2007
- Cost-of-Illness Methodology: A Guide to Current Practices and ProceduresThe Milbank Memorial Fund Quarterly. Health and Society, 1982